Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

Cancer immunotherapy using monoclonal antibodies targeting immune checkpoints has undoubtedly revolutionized the cancer treatment landscape in the last decade. Immune checkpoint inhibitors can elicit long-lasting, previously unheard-of responses in a number of tumor entities. Yet, even in such tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tschernia, Nicholas P., Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986721/
https://www.ncbi.nlm.nih.gov/pubmed/35353346
http://dx.doi.org/10.1007/s40259-022-00521-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986721/
https://www.ncbi.nlm.nih.gov/pubmed/35353346
http://dx.doi.org/10.1007/s40259-022-00521-1

Ejemplares similares